Relapse after HSCT 2021 | MILs as a source of T-cells for adoptive cellular therapy
Christoph Schmid
• 29 Sep 2021
Christoph Schmid, MD, University of Augsburg, Augsburg, Germany, discusses the benefits of marrow-infiltrating lymphocytes (MILs) as a source for adoptive cellular therapy. Dr Schmid reports that due to the unique properties of bone marrow T-cells, mainly their interaction with their microenvironment, they are promising candidates for adoptive cellular therapy. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.
Disclosures
Christoph Schmid, MD, has received research and travel grants from Novartis, Roche, Abbvie and Neovii; honoraria and speakers bureau from Novartis, Roche, BMS and Eurocept; and is also on the advisory boards of Novartis, Daichii, Eurocept and Roche.
